Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.07.135
Abstract: OBJECTIVE To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS… read more here.
Keywords: peritoneal cancer; tubal peritoneal; weekly paclitaxel; ovarian tubal ... See more keywords
Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Obstetrics and Gynaecology"
DOI: 10.1080/01443615.2019.1634028
Abstract: Abstract The aim of this study was to evaluate overall survival (OS) and disease-free survival (DFS) of patients with Stage 3C serous ovarian, tubal and peritoneal carcinomas. A retrospective analysis of 111 patients who underwent… read more here.
Keywords: tubal peritoneal; optimal cytoreductive; cancer; ovarian tubal ... See more keywords